相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
A. Y. Shah et al.
EUROPEAN JOURNAL OF CANCER (2019)
Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma
Harvey Yu-Li Su
CLINICAL GENITOURINARY CANCER (2018)
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
Rosa Maria Nadal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
Chung-Han Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
M. Taylor et al.
ANNALS OF ONCOLOGY (2017)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes et al.
TRENDS IN IMMUNOLOGY (2016)
Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation
Christopher J. D. Wallis et al.
UROLOGY (2016)
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
Aurelie Guislain et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
D. F. McDermott et al.
EUROPEAN JOURNAL OF CANCER (2015)
International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J. Ko et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Asim Amin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah et al.
NATURE (2008)
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors
Anita E. M. Dirkx et al.
FASEB JOURNAL (2006)
分享论文
